Navigation Links
Martek's life'sDHA(TM) Featured in Four New Products from Spectrum Organics
Date:7/10/2008

ing that people of all ages, from infants to aging adults, benefit from an adequate supply of DHA omega-3 in the diet. Scientific reviews highlight the importance of DHA omega-3 in proper brain and eye development and function, and clinical studies are underway to evaluate the role of DHA in decreasing the prevalence of certain neurological disorders.

Studies have shown that increased availability of DHA omega-3 during pregnancy and lactation nourishes the neurological, visual and nervous system development of babies and may play a role in long-term infant health and maternal well-being. Expert bodies have recommended that pregnant and nursing women consume at least 200 mg of DHA per day. Yet research shows that pregnant and nursing women consume, on average, only 52 mg of DHA per day. Additionally, expert bodies such as the FDA have advised pregnant and nursing women to limit their consumption of certain types of fish, the primary dietary source of DHA, due to the potentially high levels of contaminants such as mercury found in certain fish.

DHA is especially important for healthy growth and development during the early stages of life when the brain, eyes and nervous system are growing and developing at a rate unlike any other time in the human lifecycle. Studies have shown that babies who receive DHA supplementation exhibit a range of advantages over those who did not receive DHA supplementation, including cognitive and visual benefits.

Fish are often thought to be the only source of DHA omega-3. However, life'sDHA offers a trusted, vegetarian form of DHA that contains no oceanic pollutants and toxins. Fish are a good source of DHA because of the DHA-rich microalgae in their food chain; life'sDHA is derived from microalgae and produced in an FDA-inspected facility, from start to finish, using a sustainable source that does not deplete ocean resources. life'sDHA is found in numerous foods, beverages and supplements for people of all ages. It is
'/>"/>

SOURCE Martek Biosciences
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. A classic method for modeling skin cancer is featured in Cold Spring Harbor Protocols
2. Replidyne Pipeline Featured at 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy
3. Photo: Kyphon and the X-STOP(R) IPD(R) Procedure to be Featured on American Health Radio on Monday, September 24, 2007
4. Allscripts Featured in Microsoft HealthVault Worldwide Launch
5. Health Courts Critic to be Featured Speaker at Wyoming Patient Safety Panel
6. Marteks lifesDHA(TM) Featured in New Beech-Nut(R) DHA Plus Baby Food and Cereals
7. Jenny McCarthy Featured at National Autism Conference in Atlanta, November 9
8. Morris Animal Foundation Featured on NASCAR Racecar to Raise Awareness of Pet Cancer
9. Effective Treatment for Fibromyalgia Featured on Oprah Winfrey Show You Dont Have to Live With That Agony!
10. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
11. Marteks lifesDHA(TM) Featured in Dalco Foods Wellness Line Meat Products
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 2Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 3Published Data Demonstrate Arena Pharmaceuticals' Lorcaserin Has Low Abuse Potential 4ARKRAY, Inc. Receives FDA 510k Clearance on the Assure(R) Platinum Auto-Code Blood Glucose Monitoring System 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 2FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 3FDA Grants Cequent IND - Clears Way for First-Ever Clinical Trial of Orally Delivered RNAi Therapeutic: CEQ508, a tkRNAi Drug Candidate in Oncology 4Winter Spare the Air Alert in Effect for Thursday November 26 2009 62162 1Winter Spare the Air Alert in Effect for Thursday November 26 2009 62162 2Heska Announces Supply Agreement With Roche Diagnostics 6549 1Heska Announces Supply Agreement With Roche Diagnostics 6549 2Heska Announces Supply Agreement With Roche Diagnostics 6549 3Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 1Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 2Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 3Engineers doctors at UCLA develop novel material that could help fight arterial disease 62158 4